Skip to main content
. 2018 May 11;9(36):24548–24560. doi: 10.18632/oncotarget.24647

Figure 5. The efficacy evaluation of apatinib in the phase III clinical trial in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma.

Figure 5

(A) Kaplan-Meier estimates of overall survival (OS). (B) Kaplan-Meier estimates of progression free survival (PFS). (Cited from: Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34: 1448-54. doi: 10.1200/JCO.2015.63.5995.)